Bespoke Extracts (BSPK) Cash & Current Investments (2011 - 2025)
Bespoke Extracts (BSPK) reported Cash & Current Investments of $16743.0 for Q3 2025, down 21.93% on a YoY basis from $21445.0 in Q3 2024, and up 1128.39% sequentially from $1363.0 in Q2 2025.
Bespoke Extracts (BSPK) Cash & Current Investments (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 15 years of Cash & Current Investments data on file, last reported at $16743.0 in Q3 2025.
- For the quarter ending Q3 2025, Cash & Current Investments fell 21.93% year-over-year to $16743.0; the trailing twelve-month figure through Sep 2025 stood at $16743.0 (down 21.93% YoY), and the FY2024 full-year result was $60305.0, up 812.74% from the prior year.
- Cash & Current Investments advanced to $16743.0 in Q3 2025, from $1363.0 in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $501560.0 in Q1 2021 to a low of $1363.0 in Q2 2025.
- A 5-year average of $53842.3 and a median of $22150.5 in 2022 frame the typical range for Cash & Current Investments.
- Peak annual rise in Cash & Current Investments reached 27522.92% in 2021, while the deepest fall reached 97.56% in 2021.
- Tracing BSPK's Cash & Current Investments over 5 years: stood at $6295.0 in 2021, then soared by 288.13% to $24433.0 in 2022, then tumbled by 72.96% to $6607.0 in 2023, then surged by 812.74% to $60305.0 in 2024, then slumped by 72.24% to $16743.0 in 2025.
- Business Quant data shows BSPK's Cash & Current Investments at $16743.0 in Q3 2025, $1363.0 in Q2 2025, and $30365.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | 16,743.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 16,743.00 |
| Jun 30, 2025 | 1,363.00 |
| Mar 31, 2025 | 30,365.00 |
| Dec 31, 2024 | 60,305.00 |
| Sep 30, 2024 | 21,445.00 |
| Jun 30, 2024 | 24,791.00 |
| Mar 31, 2024 | 14,416.00 |
| Dec 31, 2023 | 6,607.00 |
| Jun 30, 2023 | 1,947.00 |
| Mar 31, 2023 | 4,365.00 |
| Dec 31, 2022 | 24,433.00 |
| Sep 30, 2022 | 22,856.00 |
| Jun 30, 2022 | 36,574.00 |
| Mar 31, 2022 | 100,774.00 |
| Nov 30, 2021 | 6,295.00 |
| Aug 31, 2021 | 11,177.00 |
| May 31, 2021 | 83,145.00 |
| Feb 28, 2021 | 501,560.00 |
| Nov 30, 2020 | 258,246.00 |
| Aug 31, 2020 | 126,603.00 |